Presentation is loading. Please wait.

Presentation is loading. Please wait.

Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode  Tuomas Jartti, MD, Riitta Nieminen, BM, Tytti Vuorinen,

Published byJosef Aamodt Modified over 5 years ago

Similar presentations

Presentation on theme: "Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode  Tuomas Jartti, MD, Riitta Nieminen, BM, Tytti Vuorinen,"— Presentation transcript:

1 Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode 
Tuomas Jartti, MD, Riitta Nieminen, BM, Tytti Vuorinen, MD, Pasi Lehtinen, MD, Tero Vahlberg, MSc, James Gern, MD, Carlos A. Camargo, MD, DrPH, Olli Ruuskanen, MD  Journal of Allergy and Clinical Immunology  Volume 135, Issue 3, Pages e9 (March 2015) DOI: /j.jaci Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Study flow chart. ED, Emergency department; ICU, intensive care unit; neg., negative; RV, rhinovirus. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Time to a new physician-confirmed wheezing episode in children randomized to receive prednisolone or placebo for their first rhinovirus-induced wheezing episode. The 2-month time point, which was one of the primary outcomes, has been marked. No difference was found at the 2-month or 12-month time points. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Time to a new physician-confirmed wheezing episode in children randomized to receive prednisolone or placebo for their first rhinovirus-induced wheezing episode. Data are represented according to rhinovirus load. P values for interaction between the study drug and rhinovirus load are shown at the 2-month and 12-month follow-ups. Children with a rhinovirus load of greater than 7000 copies/mL had significantly less recurrence at both time points in the prednisolone group compared with the placebo group (see text for details). All children with a high rhinovirus load in the placebo group had a relapse within 100 days. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 The key questions of parental interview and wheezy questionnaire. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E1 The key questions of parental interview and wheezy questionnaire. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E1 The key questions of parental interview and wheezy questionnaire. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E2 Clinical score sheet for hospitalized patients.
Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E3 Symptom and medication diary for 2 weeks after discharge.
Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig E4 Symptom and medication diary from 2 weeks to 2 months after discharge. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

11 Fig E5 Symptom and medication diary from 2 months to 12 months after discharge. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode  Tuomas Jartti, MD, Riitta Nieminen, BM, Tytti Vuorinen,"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD 

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD 
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema  Pasi Lehtinen, MD, Aino Ruohola,

Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema  Pasi Lehtinen, MD, Aino Ruohola,
Megan E. Jensen, PhD, Morton J

Megan E. Jensen, PhD, Morton J
Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,

Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives  Iris M. Otani, MD, Sandra C. Christiansen, MD, Paula Busse, MD,

Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives  Iris M. Otani, MD, Sandra C. Christiansen, MD, Paula Busse, MD,
Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,

Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
David A. Khan, MD  Journal of Allergy and Clinical Immunology 

David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma  Christine L.M. Joseph,

Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma  Christine L.M. Joseph,
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?

Similar presentations

Ads by Google